Novartis за 1,1 млрд долларов покупает биотех Myricx для разработки новых методов лечения рака

Швейцарский фармацевтический гигант Novartis заключил сделку по приобретению компании Myricx Bio, чтобы внедрить инновационную платформу для таргетной терапии онкологических заболеваний. Транзакция, предусматривающая до 400 миллионов долларов дополнительных выплат, должна быть завершена во второй половине 2026 года.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

The acquisition would add Myricx’s N-myristoyltransferase inhibitor (NMTi) payload platform, which is designed to deliver targeted cancer therapies with a novel mechanism aimed at overcoming limitations of existing ADC treatments. Deal Terms Under the agreement, Novartis will pay $1.1 billion upfront to acquire Myricx Bio, with up to $400 million in additional milestone payments. The transaction is expected to close during the second half of 2026. Novel ADC Platform Targets Resistant Tumors According to Novartis, Myricx has developed a differentiated ADC platform that uses NMTi payloads to selectively target tumor cells. The company believes the technology could address some of the challenges associated with widely used ADC payloads, including TOPO-1 inhibitors. Myricx is currently advancing two lead programs targeting B7-H3 and HER2, with potential applications across multiple solid tumor types. Fiona Marshall, president of Biomedical Research at Novartis, said ADCs have become an important component of cancer treatment but noted there remains a need for new payload mechanisms that can overcome treatment resistance and expand patient benefit. Marshall said Myricx’s NMTi platform offers a differentiated approach that could broaden the use of ADCs across several tumor settings. Technology Could Expand Future ADC Applications N-myristoyltransferase is an enzyme required for the proper functioning of proteins that help cancer cells grow and survive. Myricx’s approach is designed to inhibit the enzyme, disrupting critical cellular processes that tumors depend on. Novartis said preclinical data suggest the NMTi payload has broad activity across solid tumors, including models resistant to TOPO-1 inhibitors. If clinically validated, the platform could establish NMTi as a new class of ADC payloads that may be applied to additional drug targets and therapeutic platforms. NVS Price Action: Novartis shares were down 2.89% at $155.28 at the time of publication on Monday, according to Benzinga Pro data. Photo via Shutterstock © 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. To add Benzinga News as your preferred source on Google, click here.